Search

everythinglearnresearchcommunity

for

Search:↓

The study found that sweat glands normally suppress immune responses, but this is disrupted in certain skin diseases, possibly contributing to their development.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

A patient's skin rash did not affect the area where a previous viral rash was healing, suggesting a rare immune response.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Trichohyalin in hair can trigger immune attacks in alopecia areata.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

ILC1 cells contribute to hair loss in alopecia areata.

Innate immunity genes in hair follicle stem cells might have new roles beyond traditional immune functions.

Skin stem cells remember past inflammation, helping them respond better to future injuries and possibly aiding in treating skin issues.

New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.

Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

IL-15 helps protect hair follicles from immune attacks and encourages hair growth.

Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.

Transplant patients often get skin problems, with treatments varying by condition.

Breast implants are linked to autoimmune symptoms, with over half of patients feeling better after removal, but the exact cause is unclear and may involve bacterial biofilm.

Immunocompromised patients can develop skin and hair issues due to a virus.

Collagen VII helps skin heal and stay strong, sirolimus may lower skin cancer risk in kidney transplant patients, high-molecular-mass hyaluronan helps naked mole rats resist cancer, dermal γδ T cells aid in hair growth in rodents, and overexpression of IL-33 in mouse skin causes itchiness, offering a model for studying allergic inflammation treatments.

Type 2 immunity helps control mite growth in hair follicles, preventing damage.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.

Injecting anti-herpes antibodies locally can prevent skin lesions and sweating problems caused by herpes simplex virus in mice.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

A parasite-derived molecule speeds up skin healing and affects immune cell behavior without increasing scarring.